Congress file s1414-119, before Congress. Still to be decided as of 2026-07-27.
Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
Biosimilar drugs get to patients sooner The FDA no longer requires makers to run costly clinical efficacy tests unless the agency says they are needed; this cuts approval time and development costs, potentially bringing lower-cost versions of expensive biologics to market years faster.
Drug prices could fall as competitors enter market Faster approval for biosimilars means more competition with brand-name biologics, which typically costs tens of thousands of dollars per patient annually; this may push prices down across the market and free up money for other health spending.
FDA may skip safety checks in some cases The law lets the FDA skip clinical testing if it decides a test is not needed, but it does not require the agency to say why it made that choice until after an application is filed; patients and doctors may not know whether a biosimilar was tested as thoroughly as the original drug.
This bill modifies statutory requirements for demonstrating that a proposed biological product (e.g., a drug or vaccine) is biosimilar to a reference (brand-name) product. Specifically, the bill eliminates the need for a clinical efficacy study unless the Food and Drug Administration (FDA) determines such a study is necessary.Under current law, applicants seeking FDA approval of a proposed biosimilar must submit certain studies and assessments, including a clinical efficacy study demonstrating the safety, purity, and potency of the proposed biosimilar in relevant conditions of use. However, the FDA has discretion not to require studies and assessments it deems unnecessary. (For example, the FDA released draft guidance in October 2025 indicating that clinical efficacy studies may be unnecessary for a class of proposed biosimilars, known as therapeutic protein products, in some circumstances.)The bill generally eliminates the requirement that a biosimilar applicant submit a clinical efficacy study but authorizes the FDA to require such a study if necessary. If requiring a clinical efficacy study, the FDA must provide a written determination of necessity to the applicant within a spec
Read the official record for s1414-119
See everything up for a vote · This week in Congress · See what we have filed with the clerk